Obscurin (OBSCN)

Obscurin is a family of giant cytoskeletal proteins encoded by the OBSCN gene, characterized by a modular domain structure that includes immunoglobulin-like (Ig), fibronectin III (FNIII), calmodulin-binding, SH3, RhoGEF, pleckstrin homology (PH), and kinase domains[1][2]. Obscurin proteins localize to striated muscle, where they play essential roles in sarcomere organization, myofibrillogenesis, and membrane-cytoskeletal interactions via binding to titin, calmodulin, myosin, ankyrin-B, and other partners[1][2]. Some isoforms possess kinase activity and regulate protein phosphorylation (e.g., N-cadherin), while the RhoGEF domain can specifically activate RhoA and TC10, linking structural organization with intracellular signaling[2]. Deficiency, mutations, or altered splicing of OBSCN are implicated in diverse myopathies, cardiomyopathies (including left ventricular noncompaction), and possibly cancer[1]. Obscurin is not a classical drug target such as an enzyme, transporter, or receptor, but rather a multi-domain scaffolding/signal integrating protein, and currently no drugs are known to act directly on it[1][2]. OBSCN encodes giant proteins (~800 kDa or larger) and smaller variants via alternative splicing[1][2]. Obscurin interacts with key proteins (titin, myosin, calmodulin, ankyrin-B, N-cadherin, Na/K ATPase) to control sarcomere integrity, membrane linkage, and signal transduction[1][2]. Disease mutations cluster in kinase and RhoGEF domains; deficiency causes myofibril instability, sarcolemma damage, and features consistent with muscular dystrophy in model organisms[1]. No drugs are approved or in clinical use that target obscurin directly; thus there are currently no known drug mechanisms or safety concerns related to therapeutic modulation of this protein[1][2].

Other names

ObscurinOBSCNKIAA1556KIAA1639Obscurin-MLCKUNC89ARHGEF30Obscurin-RhoGEFObscurin-myosin light chain kinaseRHABDO1